BIM
CLDX icon

Bogle Investment Management’s Celldex Therapeutics CLDX Stock Holding History

Bogle Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-66,412
Closed -$4.02M – 340
2016
Q3 		$4.02M Sell
66,412
-61,744
-48% -$3.85M 0.29% 112
2016
Q2 		$8.44M Buy
+128,156
New +$8.14M 0.58% 63

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bogle Investment Management's CLDX Position: Q4 2016 in Review

Bogle Investment Management sold out of Celldex Therapeutics (CLDX) in Q4 2016, closing a stake of 66,412 shares — an estimated $4.02M sold.

Bogle Investment Management first reported a position in CLDX in Q2 2016 and held it in 2 quarters. The position peaked at $8.44M in Q2 2016. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • Bogle Investment Management reported no remaining Celldex Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Bogle Investment Management sold 66,412 Celldex Therapeutics shares in Q4 2016, an estimated $4.02M.
  • Bogle Investment Management first reported a position in Celldex Therapeutics in Q2 2016 and held it in 2 quarters.
  • Bogle Investment Management's Celldex Therapeutics position peaked at $8.44M in Q2 2016.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on Bogle Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.